United Therapeutics (UTHR) Equity Ratio (2009 - 2026)

United Therapeutics has disclosed Equity Ratio across 18 years of filings, most recently posting 0.88 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.88, changed 0.02% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.88 (changed 0.02% YoY), and the FY2025 annual result was 0.9, up 2.91% from the prior year.
• Equity Ratio came in at 0.88 for Q1 2026 at United Therapeutics, down from 0.9 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.91 in Q2 2025 to a low of 0.78 in Q2 2022.
• The 5-year median for Equity Ratio is 0.84 (2023), against an average of 0.84.
• Across the five-year window, Equity Ratio climbed 7.05% in 2025 and dropped 0.02% in 2026, its largest moves.
• United Therapeutics' Equity Ratio stood at 0.79 in 2022, then increased by 5.23% to 0.84 in 2023, then rose by 4.79% to 0.88 in 2024, then increased by 2.91% to 0.9 in 2025, then retreated by 2.4% to 0.88 in 2026.
• The last three Equity Ratio figures came in at 0.88 (Q1 2026), 0.9 (Q4 2025), and 0.9 (Q3 2025), per Business Quant data.